These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1466 related articles for article (PubMed ID: 34899748)

  • 21. Cancer Immunotherapies Based on Genetically Engineered Macrophages.
    Cannac M; Nikolic J; Benaroch P
    Cancer Immunol Res; 2022 Oct; 10(10):1156-1166. PubMed ID: 36083784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing cellular immunotherapy with macrophages.
    Mishra AK; Malonia SK
    Life Sci; 2023 Sep; 328():121857. PubMed ID: 37307965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
    Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Front Immunol; 2021; 12():738456. PubMed ID: 34721401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
    Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
    Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.
    Xia X; Yang Z; Lu Q; Liu Z; Wang L; Du J; Li Y; Yang DH; Wu S
    Mol Cancer; 2024 Aug; 23(1):175. PubMed ID: 39187850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-eating immune cells kitted out with CARs.
    Dolgin E
    Nat Biotechnol; 2020 May; 38(5):509-511. PubMed ID: 32393919
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
    Peng L; Sferruzza G; Yang L; Zhou L; Chen S
    Cell Mol Immunol; 2024 Oct; 21(10):1089-1108. PubMed ID: 39134804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.